phenyl acetate has been researched along with MODS in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asahara, T; Hayakawa, K; Ikegawa, H; Kuwagata, Y; Matsushima, A; Nomoto, K; Ogura, H; Shimazu, T; Shimizu, K; Tasaki, O | 1 |
| Atalay, F; Cadirci, E; Coskun, AK; Halici, Z; Mentes, O; Odabasoglu, F; Oral, A; Suleyman, H; Yigiter, M | 1 |
| Abraham, E; Bandi, V; Dmitrienko, A; Farid, N; Forgue, ST; Gervich, D; Jiang, F; Lowry, SF; Macias, W; Naum, C; Schein, RM; Skerjanec, S; Wunderink, R | 1 |
| Abraham, E; Dmitrienko, A; Fukiishi, Y; Laterre, PF; Steingrub, J; Zeiher, BG | 1 |
| Ekşioğlu-Demiralp, E; Ercan, F; Gedik, N; Sakarcan, A; Sehirli, O; Sener, E; Sener, G; Yeğen, BC | 1 |
| Hörl, WH; Riegel, W | 1 |
1 review(s) available for phenyl acetate and MODS
| Article | Year |
|---|---|
Cardiac depressant factors in renal disease.
Topics: Acetates; Animals; Cardiomyopathies; Heart; Humans; Ions; Kidney Diseases; Kidney Failure, Chronic; Multiple Organ Failure; Myocardium; Parathyroid Hormone; Receptors, Adrenergic, beta; Renal Dialysis; Uremia | 1993 |
2 trial(s) available for phenyl acetate and MODS
| Article | Year |
|---|---|
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
Topics: Acetates; Aged; Cause of Death; Critical Illness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Group II Phospholipases A2; Hospital Mortality; Humans; Indoles; Inflammation; Infusions, Intravenous; Keto Acids; Male; Middle Aged; Molecular Weight; Multiple Organ Failure; Phospholipases A; Phospholipases A2; Proportional Hazards Models; Prospective Studies; Safety; Survival Analysis; Systemic Inflammatory Response Syndrome; Time Factors; Treatment Outcome; United States | 2003 |
LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis.
Topics: Acetates; Double-Blind Method; Europe; Female; Group II Phospholipases A2; Humans; Indoles; Infusions, Intravenous; Keto Acids; Male; Middle Aged; Multiple Organ Failure; Phospholipases A; Phospholipases A2; Risk; Sepsis; United States | 2005 |
3 other study(ies) available for phenyl acetate and MODS
| Article | Year |
|---|---|
Gut microbiota and environment in patients with major burns – a preliminary report.
Topics: Acetates; Adult; Aged; Bacteroidaceae; Bifidobacterium; Burns; Butyrates; Clostridium; Enterobacteriaceae; Enterococcus; Fatty Acids; Feces; Female; Gastrointestinal Microbiome; Humans; Lactobacillus; Male; Middle Aged; Multiple Organ Failure; Propionates; Pseudomonas; Staphylococcus; Systemic Inflammatory Response Syndrome | 2015 |
The effects of montelukast on antioxidant enzymes and proinflammatory cytokines on the heart, liver, lungs, and kidneys in a rat model of cecal ligation and puncture-induced sepsis.
Topics: Acetates; Animals; Cecum; Cyclopropanes; Cytokines; Disease Models, Animal; Glutathione; Heart; Kidney; Lipid Peroxides; Liver; Lung; Multiple Organ Failure; Myocardium; Peroxidase; Protective Agents; Quinolines; Rats; Reactive Oxygen Species; Sepsis; Sulfides; Superoxide Dismutase | 2011 |
Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast.
Topics: Acetates; Animals; Antioxidants; Apoptosis; Blood Urea Nitrogen; Collagen; Creatinine; Cyclopropanes; Glutathione; Interleukin-1beta; Interleukin-6; Kidney; Kidney Failure, Chronic; L-Lactate Dehydrogenase; Leukocytes; Leukotriene Antagonists; Lung; Male; Malondialdehyde; Membrane Proteins; Multiple Organ Failure; Quinolines; Random Allocation; Rats; Rats, Wistar; Receptors, Leukotriene; Sulfides; Tumor Necrosis Factor-alpha | 2007 |